{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:33:45Z","timestamp":1787758425611,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Uremic pruritus or chronic kidney disease-associated pruritus (CKD-aP) is a frequent compromising symptom in end-stage renal disease. Despite the little attention paid to drugs used among hemodialysis (HD) patients, investigating medications used in this population of patients and examining the status of CKD-aP may lead to the identification of medications that improve or worsen the pruritus condition. We aimed to assess the role of underlying diseases-related drugs on CKD-aP in HD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We performed a case \u2212 control study on HD patients aged over 18 years old. The demographic data and clinical parameters including HD parameters, drug history, dermatologic assessments, and laboratory examination were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We compared 128 patients with CKD-aP as cases and 109 patients without CKD-aP as controls. Cases were on the longer course of dialysis (44.69 \u00b1 43.24 months for cases vs. 38.87 \u00b1 50.73 months for controls;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). In multiple analyses of variables related to CKD-aP, backward LR logistic regression revealed that only atorvastatin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036) was considered to be a predictive factor associated with CKD-aP. Thus, the use of atorvastatin reduced the index of CKD-aP (95% confidence interval: 0.256\u20130.954, odd's Ratio = 0.494).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Atorvastatin was associated with decreased frequencies of CKD-aP among HD patients in our study. This knowledge may guide further clinical trials to evaluate atorvastatin's immunomodulatory and anti-inflammatory effects on the CKD-aP in HD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_633_21","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:18:06Z","timestamp":1669339086000},"page":"86","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The impact of underlying diseases-related drugs on the chronic kidney disease-associated pruritus in hemodialysis patients"],"prefix":"10.4103","volume":"27","author":[{"given":"Seyyede Zeinab","family":"Azimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Ramezanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Monfared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan Kazemnejad","family":"Leili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-86-20240830","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/ndt\/gfm375","article-title":"Skin barrier structure and function and their relationship to pruritus in end-stage renal disease","volume":"22","author":"Yosipovitch","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R2-86-20240830","first-page":"1","article-title":"Pruritus: Control of itch in patients undergoing dialysis","volume":"15","author":"Mettang","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"R3-86-20240830","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-Associated Pruritus: New insights into diagnosis, pathogenesis, and management","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int Rep"},{"key":"R4-86-20240830","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: International results from the dialysis outcomes and practice patterns study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R5-86-20240830","first-page":"241","article-title":"The impact of pruritus on the quality of life of patients undergoing dialysis: A single centre cohort study","volume":"22","author":"Tessari","year":"2009","journal-title":"J Nephrol"},{"key":"R6-86-20240830","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11136-011-9964-x","article-title":"Assessment of the psychological burden associated with pruritus in hemodialysis patients using the kidney disease quality of life short form","volume":"21","author":"Lopes","year":"2012","journal-title":"Qual Life Res"},{"key":"R7-86-20240830","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-86-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASW.0000721168.40561.a3","article-title":"Validity of the fitzpatrick skin phototype classification in Ecuador","volume":"33","author":"Fors","year":"2020","journal-title":"Adv Skin Wound Care"},{"key":"R9-86-20240830","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00015550152384236","article-title":"A questionnaire for the assessment of pruritus: Validation in uremic patients","volume":"81","author":"Yosipovitch","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"R10-86-20240830","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.V451205","article-title":"Second generation logarithmic estimates of single-pool variable volume Kt\/V: An analysis of error","volume":"4","author":"Daugirdas","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"R11-86-20240830","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0971-4065.168141","article-title":"Assessment of hemodialysis adequacy in patients with chronic kidney disease in the hemodialysis unit at Tanta University Hospital in Egypt","volume":"26","author":"El-Sheikh","year":"2016","journal-title":"Indian J Nephrol"},{"key":"R12-86-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.ajkd.2007.03.010","article-title":"An update on pruritus associated with CKD","volume":"50","author":"Patel","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R13-86-20240830","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ijd.14125","article-title":"Chronic generalized pruritus without primary skin lesions: A longitudinal prospective observational study","volume":"58","author":"Alizadeh","year":"2019","journal-title":"Int J Dermatol"},{"key":"R15-86-20240830","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ndt\/gfi204","article-title":"The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients","volume":"21","author":"Kimmel","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R16-86-20240830","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/toxins10010033","article-title":"Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update","volume":"10","author":"Vanholder","year":"2018","journal-title":"Toxins (Basel"},{"key":"R17-86-20240830","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1681\/ASN.2005121341","article-title":"Statins and renal diseases: From primary prevention to renal replacement therapy","volume":"17","author":"D\u2019Amico","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R18-86-20240830","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3892\/mmr.2017.7368","article-title":"Anti-inflammatory actions of gabapentin and pregabalin on the substance P-induced mitogen-activated protein kinase activation in U373 MG human glioblastoma astrocytoma cells","volume":"16","author":"Yamaguchi","year":"2017","journal-title":"Mol Med Rep"},{"key":"R19-86-20240830","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5414\/CNP66184","article-title":"Uremic pruritus is associated with higher kt\/V and serum calcium concentration","volume":"66","author":"Duque","year":"2006","journal-title":"Clin Nephrol"},{"key":"R20-86-20240830","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0906-6705.2004.00208.x","article-title":"Statins: Novel additions to the dermatologic arsenal?","volume":"13","author":"Namazi","year":"2004","journal-title":"Exp Dermatol"},{"key":"R21-86-20240830","first-page":"CD003697","article-title":"Statins and fibrates for preventing melanoma","volume":"(4)","author":"Dellavalle","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-86-20240830","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1084\/jem.20051129","article-title":"Isoprenoids determine Th1\/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin","volume":"203","author":"Dunn","year":"2006","journal-title":"J Exp Med"},{"key":"R23-86-20240830","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1189\/jlb.0608382","article-title":"Statins alter neutrophil migration by modulating cellular Rho activity \u2013 A potential mechanism for statins-mediated pleotropic effects?","volume":"85","author":"Maher","year":"2009","journal-title":"J Leukoc Biol"},{"key":"R24-86-20240830","first-page":"187","article-title":"Simvastatin-induced lichen planus pemphigoides","volume":"130","author":"Stoebner","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"R25-86-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/vhrm.2006.2.1.87","article-title":"Evaluation of efficacy and safety of fixed dose lovastatin and niacin (ER) combination in asian Indian dyslipidemic patients: A multicentric study","volume":"2","author":"Sharma","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"R26-86-20240830","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-4632.2010.04579.x","article-title":"Statins in dermatology","volume":"49","author":"Jowkar","year":"2010","journal-title":"Int J Dermatol"},{"key":"R27-86-20240830","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/eurheartj\/ehn138","article-title":"Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up","volume":"29","author":"Guasti","year":"2008","journal-title":"Eur Heart J"},{"key":"R28-86-20240830","first-page":"A225","article-title":"Effect of valsartan and carvedilol on TNF\u03b1, IL-6 and angiotensin A on geriatric chronic heart failure","volume":"97","author":"Xianghong","year":"2011","journal-title":"Heart"},{"key":"R29-86-20240830","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/00015555-0650","article-title":"Drug-induced pruritus: A review","volume":"89","author":"Reich","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R30-86-20240830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_633_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:42Z","timestamp":1787757402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_633_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_633_21","relation":{},"ISSN":["1735-1995"],"issn-type":[{"value":"1735-1995","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}